Latest Health & Nutrition News and Videos
Natural beauty is increasingly recognized as a v
Are you looking to boost your intake of dihydroq
Longevity.
Aspen Neuroscience announced completion of dosing
GC Therapeutics’ plug-and-play stem cell progr
Personality changes throughout life can impact m
Global industry leaders converge in Singapore to
VO2 max, or maximal oxygen uptake, is the ultima
Longevity.
As the International Longevity Summit approaches
A new study reveals that baking soda, also known
Supersets are gaining attention as a time-effici
Imagine noticing subtle changes in your memory o
Longevity.
Phase 2 study data indicates ‘dose-dependent i
Company aims to inhibit SARM1 enzyme to prevent
A new study highlights how three key blood marke
Have you ever questioned whether even a small di
Longevity.
Designed to protect key retinal cells, company’s Fas inhibitor drugs aim to prevent vision loss in a range of conditions. With the world buzzing about Neuralink’s latest project to restore sight to the blind, others take the view that prevention is better than cure. To that end, US biopharma ONL Therapeutics has completed an oversubscribed $65 million Series D financing round to advance the clinical development of its novel therapeutics aimed at protecting retinal cells. ONL’s approach is focused on inhibiting Fas-mediated cell death, a critical mechanism in many ophthalmic diseases. Fas signaling plays a dual role in activating cell death and regulating immune responses, which can further damage retinal cells. The company’s lead compound, ONL1204, is a first-in-class small molecule Fas inhibitor, designed to protect key retinal cells, including photoreceptors, from Fas-induced cell death, a primary cause of vision loss in a range of conditions. By targeting Fas signaling, ONL aims to address both the direct and inflammatory pathways leading to cell death, potentially offering a broad therapeutic benefit across a range of retinal diseases. The funding will be used to initiate a global Phase 2 study in patients suffering from geographic atrophy (GA) linked to dry age-related macular degeneration (AMD).…
Collaboration aims to empower health practitione
TVM Capital Healthcare has announced a strategic
Probiotics are often viewed as the solution to v
A recent study highlights that the “pregnancy
Coya Therapeutics is pioneering multi-pathway th
Elon Musk claims that experimental ‘Blindsight
Achieving glowing skin is a goal for many, and c
Longevity.
Boosting cellular regeneration, reducing inflamm
Different diets have been linked to promoting he
Finding purpose and balance often feels elusive
Chai Discovery emerges with $30m in funding and
Can a simple drink help you shed those stubborn
Longevity.
Zurich-based venture capital firm Ayun has launch
A new study considers epigenetic aging from a si